News

Biocon rises after EU approves pertuzumab biosimilar for breast cancer treatment

18-Nov-2026 | 11:14
Biocon rose 1.49% to Rs 364.75 after the European Commission (EC) granted marketing authorisation to its pertuzumab biosimilar, Pebrilzo, for treating HER2-positive breast cancer across multiple disease stages in the European Union.
The approval makes Biocon's pertuzumab the first biosimilar to receive European Commission marketing authorisation under the European Medicines Agency's (EMA) new tailored clinical approach. It follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) on 17 September 2026.

The biosimilar is approved as a 420 mg concentrate for solution for infusion. It is indicated for use in combination with trastuzumab and chemotherapy in the neoadjuvant and adjuvant treatment of eligible adult patients with HER2-positive breast cancer. It is also approved for treating HER2-positive metastatic or locally recurrent unresectable breast cancer in combination with trastuzumab and docetaxel.

Biocon said the approval follows extensive analytical characterisation and comparative clinical pharmacokinetic studies, which demonstrated high similarity to the reference product, with no clinically meaningful differences in quality, safety or efficacy.

The European approval follows recent approval of the biosimilar by the US Food and Drug Administration (FDA).

With this development, pertuzumab becomes Biocon's fifth oncology biosimilar approved in both Europe and the US, strengthening its presence in the global oncology market.

Biocon is a Bengaluru-based global biopharmaceutical company offering biosimilars and generic medicines across more than 120 countries. Its portfolio spans diabetes, oncology, obesity, cardiovascular diseases, immunology, ophthalmology and bone health. The company has commercialised 12 biosimilar products and more than 30 generic formulations globally, with a pipeline of over 20 biosimilar assets. It operates seven manufacturing facilities and three R&D centres, employing more than 9,500 people.

On a consolidated basis, Biocon's net profit declined 51.12% to Rs 41.30 crore while net sales rose 1.94% to Rs 4345.00 crore in Q2 September 2026 over Q2 September 2025.

Powered by Capital Market - Live News